# Batlivala & Karani



## RESULT UPDATE

## MID CAP

### **Share Data**

Reuters code		SN	ГХ.ВО
Bloomberg code		SI	NT IN
Market cap. (US\$ n	nn)		703
6M avg. daily turno	ver (U	S\$ mn)	12.2
Issued shares (mn)			432
Target price (Rs)			149
Performance (%)	1M	3M	12M
Absolute	(15)	(1)	121
Relative	(9)	7	86

#### Valuation Ratios (Consolidated)

· ·		,
Yr to 31 Mar	FY16E	FY17E
EPS (Rs)	13.4	16.9
+/- (%)	3.5	26.0
$P \not = E\left(x\right)$	7.8	6.2
$P \neq B(x)$	0.9	0.8
Dividend Yield (%)	0.8	0.9
EV / Sales (x)	1.1	0.9
EV / EBITDA(x)	6.7	5.1
Major shareholder	rs (%)	
Promoters	·	34

## **Sintex Industries**

## **Maintain Outperformer**

Price: Rs 105 BSE Index: 26,599 07 May 2015

## 4QFY15 Result - Strong performance despite high YoY base!

Sintex Industries Ltd. (SINT) reported a good set of financial results for 4QFY15. Consolidated revenue grew  $\sim$ 9.7% YoY to  $\sim$ Rs 22 bn. Topline was powered by strong growth in textiles (+39.3% YoY), prefab (+19.3% YoY), and consolidated custom moulding (+15.6% YoY). 4Q EBITDA grew  $\sim$ 14.3% YoY to  $\sim$ Rs 4 bn (EBITDA margin improved +80 bps YoY to  $\sim$ 18.8%). It is pertinent to note that 4QFY14 was a very strong quarter both in terms for revenue and EBITDA. Tax rate for the quarter came in at  $\sim$ 32.4% (4QFY14 - 9.1%; 3QFY15 - 9.4%). Net income came in at  $\sim$ Rs 2 bn (+22.7% YoY).

## Key highlights

**Prefab outlook remains strong:** SINT is expecting a rerun of its strong performance in this segment ( $\pm$ 26.1% YoY in FY15) in FY16E. On the prefab front, the company is bullish on government spending initiatives (viz. Sarva Shiksha Abhiyaan and National Health Mission). The company also sees immense potential from emerging product segments like reverse osmosis plants, biogas plants for city-based restaurants and country-based homes (SINT is the only government approved vendor for small domestic scale biogas plants), sewage treatment plants in residential complexes, etc. SINT is expecting revenue growth of  $\sim$ 20%+ in this segment in FY16E. Growth can be higher if orders come in for Swachh Bharat Abhiyaan (SBA) and Corporate Social Responsibility (CSR) initiatives.

### Yarn project on track; Phase II roll out conditional on Phase I performance:

SINT's Pipavav yarn project ( $\sim$ 320k spindles) is on schedule and the first  $\sim$ 100k spindles will be operational by September 2015 and the entire phase will be operational by March 2016. The project's utilisation level is expected to be  $\sim$ 20-30% in FY16E but can ramp-up to almost full capacity in FY17E depending on market conditions. According to the management, Phase II roll out (further  $\sim$ 320k spindles) will be conditional on the performance of Phase I.

## Financial highlights (Consolidated)

28

2

36

FIIs

MFs

Public & Others

I manetal inglinights (Consolidated)												
(Rs mn)	4QFY14	4QFY15	YoY (%)	3QFY15	<b>QoQ</b> (%)	FY14	FY15	YoY (%)	FY16E	YoY (%)	FY17E	YoY (%)
Total revenue	19,831	21,763	9.7	18,329	18.7	58,426	70,066	19.9	77,465	10.6	94,831	22.4
EBITDA	3,574	4,085	14.3	3,069	33.1	9,423	11,824	25.5	13,258	12.1	16,646	25.6
EBITDA margin (%)	18.0	18.8	_	16.7	_	16.1	16.9	_	17.1	_	17.6	_
Depreciation	817	711	(13.0)	746	(4.8)	2,548	2,605	2.3	3,511	34.8	5,080	44.7
Other income	95	477	401.1	119	300.6	993	964	(2.9)	650	(32.6)	900	38.5
Interest expense	1,058	861	(18.6)	648	32.9	2,894	2,835	(2.0)	2,389	(15.7)	2,353	(1.5)
Exceptional items	1	(61)	_	(64)	_	(209)	(218)	_	_	_	_	_
PBT	1,796	2,929	63.1	1,729	69.4	4,766	7,130	49.6	8,008	12.3	10,113	26.3
Tax Expense	175	948	442.1	118	701.7	1,132	1,863	64.6	2,082	11.7	2,629	26.3
Reported PAT	1,612	1,978	22.7	1,620	22.1	3,647	5,288	45.0	5,996	13.4	7,554	26.0
Adjusted PAT	1,611	2,039	26.6	1,685	21.0	3,856	5,506	42.8	5,996	8.9	7,554	26.0
Adjusted PAT margin (%)	8.1	9.4	_	9.2	_	6.6	7.9	_	7.7	_	8.0	_
Adjusted EPS (Rs)	5.2	4.8	(7.2)	4.5	6.3	12.3	13.0	5.3	13.4	3.5	16.9	26.0

**Prefab/CM capex conditional on demand:** The management notes that current utilisation levels of its prefab (62% in FY15) and CM facilities (70% in FY15) is lower than optimal, although it is difficult to keep the average utilisation figure in the high 90s due to various market dynamics across regions where SINT has its facilities. However, the company is open to incur additional capex for such facilities if utilisation levels inch higher. The management believes that SBA/CSR order pick-up may necessitate further capex in the prefab segment in FY17-18E. In FY16E, SINT estimates ~Rs 4.5 bn capex in its prefab/CM businesses.

## Segmentwise Break-Up

- I garage								
(Rs mn)	4QFY14	4QFY15	<b>YoY</b> (%)	3QFY15	<b>QoQ</b> (%)	FY14	FY15	<b>YoY</b> (%)
Revenue								
Textiles	1,529	2,130	39.3	1,860	14.5	5,459	7,240	32.6
Monolithic (incl. EPC)	6,058	5,210	(14.0)	2,610	99.6	12,510	13,500	7.9
Prefabrication	3,446	4,110	19.3	4,130	(0.5)	11,740	14,800	26.1
Custom moulding	7,900	9,130	15.6	8,810	3.6	25,660	31,080	21.1
Tanks	930	1,080	16.1	850	27.1	3,090	3,460	12.0
EBITDA margin (%)	4QFY14	4QFY15	$\mathbf{YoY}(\mathbf{bps})$	3QFY15	$\mathbf{QoQ}(\mathbf{bps})$	FY14	FY15	YoY (bps)
Textiles	30.1	26.4	(370)	28.0	(155)	25.0	25.0	_
Monolithic (incl. EPC)	14.6	12.4	(217)	10.1	232	17.0	13.0	(400)
Prefabrication	27.6	28.1	46	26.0	206	25.7	26.0	25
Custom moulding	17.1	16.3	(86)	12.8	344	19.3	20.0	67
Tanks	14.0	13.5	(51)	11.8	173	13.8	12.0	(180)

### Outlook and valuation

We remain bullish on the prospects of SINT in the prefab and CM space. The government's strong commitment towards social spending as well as its thrust on driving infrastructure investment and its 'Make in India' manufacturing campaign, 100 smart cities are positive for the company. The improving outlook in the domestic automobile industry and client industry diversification in Europe, are positive boosters for the company's CM business. The easing working capital cycle and reduction in interest rates (high cost debt replaced by low cost TUFS debt, FCCB conversions) are also positive for net profit growth (~17% CAGR in FY15-17E). However, we continue to remain cautious on the company's continued investment in the low return spinning business.

We have marginally increased our revenue and EBITDA estimates for FY16E/FY17E to reflect the better than expected performance of the international CM business. We maintain our Outperformer rating on the stock with a SOTP target price of Rs 149.

### **Revised estimates**

	C	Old New		New		ge (%)
(Rs mn)	FY16E	FY17E	FY16E	FY17E	FY16E	FY17E
Total revenue	74,479	89,931	77,465	94,831	4.0	5.4
EBITDA	12,557	15,688	13,258	16,646	5.6	6.1
EBITDA margin (%)	16.9	17.4	17.1	17.6	_	_
Adjusted PAT	5,117	7,004	5,996	7,554	17.2	7.8
Adjusted EPS (Rs)	11.5	15.7	13.4	16.9	17.2	7.8

SINTEX INDUSTRIES 2

Income Statement	(Conso	lidated)		
Period end (Rs mn)	Mar 14	Mar 15	Mar 16E	Mar 17E
Net Sales	58,426	70,066	77,465	94,831
Growth (%)	15.0	19.9	10.6	22.4
Operating Expenses	(49,003)	(58,242)	(64,208)	(78, 185)
Operating Profit	9,423	11,824	13,258	16,646
EBITDA	9,423	11,824	13,258	16,646
Growth (%)	27.2	25.5	12.1	25.6
Depreciation	(2,548)	(2,605)	(3,511)	(5,080)
Other Income	993	964	650	900
EBIT	7,869	10,183	10,397	12,466
Finance Cost	(2,894)	(2,835)	(2,389)	(2,353)
Exceptional & Extraordina	ry (209)	(218)	0	0
Profit Before Tax	4,766	7,130	8,008	10,113
Tax (Current + Deferred)	(1,132)	(1,863)	(2,082)	(2,629)
Profit/(Loss) For The Per	iod 3,634	5,267	5,926	7,484
P / L of Associates, Min Int, Pref Div	13	21	70	70
Reported Profit/(Loss)	3,647	5,288	5,996	7,554
Adjusted Net Profit	3,856	5,506	5,996	7,554
Growth (%)	(7.1)	42.8	8.9	26.0

Balance Sheet (Con	nsolida	ted)		
Period end (Rs mn)	Mar 14	Mar 15P	Mar 16E	Mar 17E
Share Capital	311	424	445	445
Reserves & Surplus	35,127	46,553	52,529	59,613
Shareholders' Funds	35,439	46,978	52,974	60,058
Non-Current Liablities	36,236	37,851	37,561	38,311
Long-Term Borrowings	32,104	31,817	30,667	31,917
Other Long Term Liab., Provisions, DTL	4,132	6,033	6,894	6,394
<b>Current Liabilities</b>	19,281	28,249	29,294	28,244
Short-Term Borrowings, Current Maturity	7,961	10,987	13,398	9,586
Other Current Liab. + Provision	ns 11,320	17,262	15,896	18,658
Total (Equity and Liab.)	90,955	113,077	119,830	126,613
Non-Current Assets	59,211	74,484	65,523	65,443
Fixed Assets (Net Block)	37,403	52,686	53,032	52,952
Non-Current Investments	2,487	2,508	2,508	2,508
Long-Term Loans and Advance	es 16,920	17,271	7,660	7,660
Other Non-Current Assets DTA, Goodwill	s, 2,401	2,018	2,323	2,323
Current Assets	31,745	38,593	54,307	61,171
Cash & Current Investmen	ts 3,292	7,023	2,233	4,151
Other Current Assets	28,453	31,571	52,074	57,020
Total (Assets)	90,955	113,077	119,830	126,613
Total Debt	40,065	42,804	44,065	41,504
Capital Employed	79,635	95,815	103,933	107,955

Cash Flow Stateme	Cash Flow Statement (Consolidated)				
Period end (Rs mn)	Mar 14	Mar 15P	Mar 16E	Mar 17E	
Profit Before Tax	4,766	7,130	8,008	10,113	
Depreciation	2,548	2,605	3,511	5,080	
Change in Working Capita	l (6,956)	2,412	(12,334)	(2,237)	
Total Tax Paid	(722)	(458)	(2,082)	(2,629)	
Others	2,894	2,835	2,039	1,853	
Cash Flow from Oper. (a	a) 2,530	14,524	(858)	12,180	
Capital Expenditure	(7,360)	(17,888)	(3,857)	(5,000)	
Change in Investments	(1,755)	(2,223)	2,201	0	
Others	(232)	24	46	500	
Cash Flow from Inv. (b)	(9,346)	(20,087)	(1,610)	(4,500)	
Free Cash Flow (a+b)	(6,817)	(5,563)	(2,468)	7,680	
Equity Raised / (Repaid)	0	8,407	419	0	
Debt Raised / (Repaid)	3,525	2,740	1,261	(2,561)	
Dividend (incl. Tax)	(255)	(256)	(348)	(418)	
Others	(2,635)	(3,798)	(1,452)	(2,783)	
Cash Flow from Fin. (c	635	7,093	(120)	(5,763)	
Net Chg. in Cash (a+b+c	(6,182)	1,530	(2,588)	1,917	

Key Ratios (Conso	Key Ratios (Consolidated)					
Period end (%)	Mar 14	Mar 15P	Mar 16E	Mar 17E		
Adjusted EPS (Rs)	12.3	13.0	13.4	16.9		
Growth	(7.1)	5.3	3.5	26.0		
CEPS (Rs)	20.5	19.1	21.3	28.3		
Book NAV / Share (Rs)	113.2	110.7	118.6	134.5		
Dividend / Share (Rs)	0.7	0.7	8.0	0.9		
Dividend Payout Ratio	7.0	6.6	7.0	6.2		
EBITDA Margin	16.1	16.9	17.1	17.6		
EBIT Margin	13.5	14.5	13.4	13.1		
Tax Rate	22.8	25.4	26.0	26.0		
RoCE	10.4	11.6	10.4	11.8		
Net Debt / Equity (x)	1.0	0.8	8.0	0.6		
Net Debt / EBITDA $(x)$	3.9	3.0	3.2	2.2		
<b>Du Pont Analysis - RO</b>	E					
Net Margin	6.6	7.9	7.7	8.0		
Asset Turnover (x)	0.7	0.7	0.7	8.0		
Leverage Factor (x)	2.6	2.5	2.3	2.2		
Return on Equity	11.6	13.4	12.0	13.4		


Valuations (Con	solidated)			
Period end (x)	Mar 14	Mar 15P	Mar 16E	Mar 17E
PER	3.5	9.3	7.8	6.2
PCE	2.1	6.3	4.9	3.7
Price / Book	0.4	1.1	0.9	0.8
Yield (%)	1.6	0.6	0.8	0.9
EV / EBITDA	5.3	7.4	6.7	5.1

SINTEX INDUSTRIES 3


Aasim Bharde aasim.bharde@bksec.com +91-22-4031 7135

Resham Jain, CFA resham.jain@bksec.com +91-22-4031 7133





## By Recommendation



B&K Securities is the trading name of Batlivala & Karani Securities India Pvt. Ltd.

#### **B&K Investment Ratings.**

	LARGE CAP (Market Cap > USD 2 bn)	MID CAP (Market Cap of USD 200 mn to USD 2 bn)	SMALL CAP (Market Cap <usd 200="" mn)<="" th=""></usd>
BUY	>+20% (absolute returns)	>+25% (absolute returns)	>+30% (absolute returns)
OUTPERFORMER	+10% to +20%	+15% to +25%	+20% to +30%
UNDERPERFORMER	+10% to -10%	+15% to -15%	+20% to -20%
SELL	<-10% (absolute returns)	<-15% (absolute returns)	<-20% (absolute returns)

**Disclaimer:** This report was prepared, approved, published and distributed by Batlivala & Karani Securities India Private Limited ("B&K") located outside of the United States (a "non-US Group Company"), which accepts responsibility for its contents. It is distributed in the U.S. by Enclave Capital, a U.S. registered broker dealer, on behalf of B&K, only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6. Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. Outside the United States, this report is distributed by B&K or an authorized affiliate of B&K.

The report has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. B&K has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, B&K accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. B&K provides the information for the purpose of the intended recipient's analysis and review and recipients are advised to verify the factual accuracy, assumptions, calculations and completeness of the information.

This report was produced by B&K solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions. This document does not constitute an offer of, or an invitation by or on behalf of B&K or its affiliates or any other company to any person, to buy or sell any security.

**Analyst Certification:** Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

## Disclosures, applying to B&K and the Analyst (together with associates and family members)

None
110110
None
None
< 0.1%
< 0.1%
None
None

#### Important US Regulatory Disclosures on Subject Companies

- 1. B&K or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
- 2. B&K or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. B&K or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more person of B&K or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
- 5. B&K or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report.
- 6. As of the publication of this report, Enclave Capital does not make a market in the subject securities.

Enclave Capital is the distributor of this document in the United States of America. Any US customer wishing to effect transactions in any securities referred to herein or options thereon should do so only by contacting a representative of Enclave Capital and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital (19 West 44th Street, suite 1700, New York, NY 10036).

#### **B & K SECURITIES INDIA PRIVATE LTD.**

Equity Research Division: City Ice Bldg, 298, Ground/1st Floor, Perin Nariman Street, Behind RBI, Fort, Mumbai - 400 001, India. Tel.: 91-22-4031 7000, Fax: 91-22-2263 5020/30.

Registered Office: Room No. 3/4, 7 Lyons Range, Kolkata - 700 001. Tel.: 91-33-2243 7902.

B&K Research is also available on Bloomberg <BNKI>, Thomson First Call & Investext.